Picture of Athenex logo

ATNX — Athenex Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapValue Trap

Momentum

Relative Strength (%)
1m-33.86%
3m-61.55%
6m-74.8%
1yr-92.23%
Volume Change (%)
10d/3m-17.16%
Price vs... (%)
52w High-92.93%
50d MA-35.37%
200d MA-67.84%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-45.05%
Return on Equity-76.73%
Operating Margin-120.21%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Athenex EPS forecast chart

Profile Summary

Athenex, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Global Supply Chain Platform is engaged in supplying active pharmaceutical ingredient (APIs) to clinical and commercial efforts. The Commercial Platform is focused on the sales and marketing of its drugs. Its product pipeline includes Orascovery, Src Kinase Inhibition, Cell Therapy and Arginine Deprivation Therapy. Its lead product candidate Orascovery platform technology is based on the novel oral P-gp pump inhibitor molecule, encequidar. Its Src Kinase inhibition platform technology is based on novel small molecule compounds including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization.

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
November 4th, 2003
Public Since
June 14th, 2017
No. of Shareholders
97
No. of Employees
593
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
109,319,039

ATNX Share Price Performance

Similar to ATNX

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

AbSci

us flag iconNASDAQ Global Select Market

Picture of ACADIA Pharmaceuticals logo

ACADIA Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email